Mostly Markets
Subscribe
Stocks/Health Care/Biotechnology

AmgenAMGN

Biotechnology · Thousand Oaks, California · In the S&P 500
High quality
$466.01+1.15%After hours: $466.67 (+0.14%)At the close, 30 Oct · Prices from CNBC, may be delayed
▲ 59.7% over 1 year
Amgen over 1 yearDaily close, $, to 30 Oct 2026
$300$350$400$450Nov2026MarMayJulSep$466.01$300$400NovMarJul$466.01
Source: Nasdaq daily closes
Market value$252B
Price to earnings28.9x
Forward P/E19.8x
Dividend yield2.16%
Year to date+42.4%
One year+59.7%
Next earningsTue 3 Nov, after the close
SectorHealth Care
52-week range (closes)
$292.00$466.01

Quality and valuation

How Amgen compares with other health care stocks. A description, not a recommendation.

Amgen and 7 biotechnology peers. Across: valuation (P/E) against the sector. Up: business quality against the sector. Hover or tap a logo for its numbers.

Business quality: stronger than mostValuation: in line with its sector

A stronger business than most health care companies, priced about in line with them.

Amgen trades at 19.8 times the next 12 months of expected earnings, against a median of 19.1x for the 65 health care stocks we cover. The quality score blends where it ranks on revenue growth, gross margin, operating margin and free-cash-flow margin (net margin for banks and insurers) over the last 12 months, from SEC filings.

  • Revenue grew faster than the sector median: +9.1% vs +8.1%
  • Keeps more of each sale (gross margin): 69.5% vs 65.0%
  • More profitable (operating margin): 30.0% vs 13.3%
  • Turns more of its sales into cash: 26.7% vs 15.9%
AMGN trades at 19.8x forward earnings, above the sector medianForward p/e, Biotechnology peers
REGN14.3xGILD19.4xABBV19.6xAMGN19.8xBIIB20.5xVRTX29.3xINCY61.0xSector median 19.1xREGN14.3xGILD19.4xABBV19.6xAMGN19.8xBIIB20.5xVRTX29.3xINCY61.0xSector median 19.1x
Source: CNBC quotes; Mostly Markets
At 29.0x earnings, AMGN is cheaper than its average since Aug 2024Price over the last 12 months of reported (GAAP) diluted EPS
P/EUsual range (±1 s.d.)
20x40x50xAverage 31.3x2025202629.0x20x40xAverage 31.3x2025202629.0x
Source: Nasdaq prices; SEC filings

Financials

From Amgen's SEC filings, through the quarter ending 30 Jun 2026. Hover or tap a bar for its value.

Revenue grew 9.5% from a year earlierQuarterly revenue, $bn, latest Q2 ’26
$0bn$5bn$10bnQ3 ’24Q1 ’25Q3 ’25$10.1bnQ2 ’26$0bn$5bn$10bnQ3 ’24Q1 ’25Q3 ’25$10.1bnQ2 ’26
Source: SEC filings
Growth sped up to +9.5% last quarterRevenue growth, year on year, %
0%10%20%Q3 ’24Q1 ’25Q3 ’259.5%Q2 ’260%10%20%Q3 ’24Q1 ’25Q3 ’259.5%Q2 ’26
Source: SEC filings
Operating margin was 35.0% last quarterOperating income as a share of revenue, %
0%10%20%30%Q3 ’24Q1 ’25Q3 ’2535.0%Q2 ’260%20%Q3 ’24Q1 ’25Q3 ’2535.0%Q2 ’26
Source: SEC filings
Free cash flow was $10.2 billion over 12 monthsQuarterly free cash flow (operating cash flow minus capex), $bn
$0bn$2bn$4bnQ3 ’24Q1 ’25Q3 ’25$3.5bnQ2 ’26$0bn$2bn$4bnQ3 ’24Q1 ’25Q3 ’25$3.5bnQ2 ’26
Source: SEC filings
Last 12 monthsAMGNSector median
Revenue growth+9.1%+8.1%
Gross margin69.5%65.0%
Operating margin30.0%13.3%
Free cash flow margin26.7%15.9%
Price to earnings28.9x30.2x

Stories on Amgen

We haven't written about Amgen yet. Follow it, and its first story will show under My stocks on the front page.

Similar companies

Biotechnology, by market value.

CompanyPriceTodayYTDValue
ABBVAbbVie$294.89+1.41%+29.1%$521B
GILDGilead Sciences$170.68+3.06%+39.1%$212B
VRTXVertex Pharmaceuticals$558.88+3.50%+23.3%$142B
REGNRegeneron Pharmaceuticals$927.89+13.33%+20.2%$95.53B
MRNAModerna$221.72−0.47%+651.8%$88.52B
BIIBBiogen$253.62+1.59%+44.1%$37.49B
INCYIncyte$120.39+3.07%+21.9%$24.40B